Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
Samit Ganguly, Elmsford, NY (US); Jennifer Hamilton, Ridgefield, CT (US); Gary Herman, Princeton, NJ (US); Andrea Hooper, Port Chester, NY (US); Flonza Isa, Yonkers, NY (US); Meagan O'Brien, New York, NY (US); Sumathi Sivapalasingam, Brooklyn, NY (US); Kenneth Turner, Ridgefield, CT (US); and Eduardo Forleo Neto, Greenwich, CT (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Jun. 2, 2021, as Appl. No. 17/337,396.
Claims priority of provisional application 63/186,029, filed on May 7, 2021.
Claims priority of provisional application 63/185,301, filed on May 6, 2021.
Claims priority of provisional application 63/173,468, filed on Apr. 11, 2021.
Claims priority of provisional application 63/166,187, filed on Mar. 25, 2021.
Claims priority of provisional application 63/165,654, filed on Mar. 24, 2021.
Claims priority of provisional application 63/164,488, filed on Mar. 22, 2021.
Claims priority of provisional application 63/162,996, filed on Mar. 18, 2021.
Claims priority of provisional application 63/162,504, filed on Mar. 17, 2021.
Claims priority of provisional application 63/150,978, filed on Feb. 18, 2021.
Claims priority of provisional application 63/144,789, filed on Feb. 2, 2021.
Claims priority of provisional application 63/142,471, filed on Jan. 27, 2021.
Claims priority of provisional application 63/141,952, filed on Jan. 26, 2021.
Claims priority of provisional application 63/141,423, filed on Jan. 25, 2021.
Claims priority of provisional application 63/131,627, filed on Dec. 29, 2020.
Claims priority of provisional application 63/124,980, filed on Dec. 14, 2020.
Claims priority of provisional application 63/120,065, filed on Dec. 1, 2020.
Claims priority of provisional application 63/119,593, filed on Nov. 30, 2020.
Claims priority of provisional application 63/116,773, filed on Nov. 20, 2020.
Claims priority of provisional application 63/112,140, filed on Nov. 10, 2020.
Claims priority of provisional application 63/106,696, filed on Oct. 28, 2020.
Claims priority of provisional application 63/105,779, filed on Oct. 26, 2020.
Claims priority of provisional application 63/094,133, filed on Oct. 20, 2020.
Claims priority of provisional application 63/090,690, filed on Oct. 12, 2020.
Claims priority of provisional application 63/089,399, filed on Oct. 8, 2020.
Claims priority of provisional application 63/084,881, filed on Sep. 29, 2020.
Claims priority of provisional application 63/085,066, filed on Sep. 29, 2020.
Claims priority of provisional application 63/065,799, filed on Aug. 14, 2020.
Claims priority of provisional application 63/062,961, filed on Aug. 7, 2020.
Claims priority of provisional application 63/060,592, filed on Aug. 3, 2020.
Claims priority of provisional application 63/043,336, filed on Jun. 24, 2020.
Claims priority of provisional application 63/038,274, filed on Jun. 12, 2020.
Claims priority of provisional application 63/036,956, filed on Jun. 9, 2020.
Claims priority of provisional application 63/034,348, filed on Jun. 3, 2020.
Prior Publication US 2021/0395345 A1, Dec. 23, 2021
1. A method for improving one or more clinical parameters of COVID-19, the method comprising administering a therapeutic composition to a subject in need thereof, wherein the therapeutic composition comprises at least one antigen-binding molecule that binds a surface protein of SARS-CoV-2, wherein the at least one antigen-binding molecule is an anti-SARS-CoV-2 spike glycoprotein antibody or antigen-binding fragment thereof comprising three heavy chain complementarity determining regions (HCDRs) and three light chain complementarity determining regions (LCDRs), HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 contained within a heavy chain variable region (HCVR) and light chain variable region (LCVR) amino acid sequence pair comprising the amino acid sequences selected from the group consisting of SEQ ID NOs: 2 and 10, SEQ ID NOs: 22 and 30, and SEQ ID NOs: 42 and 50.